丹麦乳腺癌协作组部分乳腺照射试验中呼吸门控的获益
该研究基于丹麦乳腺癌协作组部分乳腺照射试验中230例左侧乳腺癌患者,分析呼吸门控对平均心脏剂量的影响。呼吸门控组123例(53%),其平均心脏剂量中位数0.33 Gy,自由呼吸组0.49 Gy,差异有统计学意义(P<0.0001);呼吸门控仅在上象限肿瘤床显著降低平均心脏剂量,未改善临床靶区覆盖或降低肺剂量。
要点
- 呼吸门控组平均心脏剂量中位数0.33 Gy,自由呼吸组0.49 Gy,P<0.0001。
- 呼吸门控仅在上象限肿瘤床显著降低平均心脏剂量,下象限无显著降低。
- 呼吸门控未改善临床靶区覆盖或降低肺剂量。
核心结论
- 部分乳腺照射使大多数患者平均心脏剂量较低。
- 呼吸门控进一步降低了上象限肿瘤床的平均心脏剂量,但未降低下象限肿瘤床的平均心脏剂量。
- 呼吸门控未影响靶区覆盖或肺剂量。
- 呼吸门控已不再是丹麦乳腺癌协作组左侧部分乳腺照射的标准。
研究设计与样本
- 研究纳入2009年至2016年丹麦乳腺癌协作组部分乳腺照射试验中230例接受外照射部分乳腺照射的左侧乳腺癌患者,剂量方案为40 Gy/15次/3周。
- 收集规划CT上肿瘤床定位、呼吸门控使用、临床靶区覆盖及危及器官剂量。
主要发现
- 123例(53%)患者使用了呼吸门控。
- 176例(77%)患者肿瘤床位于上象限,54例(23%)位于下象限。
- 全部患者平均心脏剂量中位数为0.37 Gy(四分位距0.26-0.57 Gy)。
- 呼吸门控组平均心脏剂量中位数为0.33 Gy(0.23-0.49 Gy),自由呼吸组为0.49 Gy(0.31-0.70 Gy),P<0.0001。
- 206例(90%)患者平均心脏剂量<1 Gy,221例(96%)患者平均心脏剂量<2 Gy。
临床怎么用
- 原文结论指出呼吸门控已不再是丹麦乳腺癌协作组左侧部分乳腺照射的标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Partial breast irradiation (PBI)has beenthe Danish Breast Cancer Group(DBCG) standard for selected breast cancer patients since 2016 based onearlyresults from the DBCG PBI trial.During trial accrual, respiratory-gated radiotherapy was introduced in Denmark. This study aims to investigate the effect of respiratory-gating on mean heart dose (MHD). PATIENTS AND METHODS: From 2009 to 2016 the DBCG PBI trial included 230 patientswith left-sided breast cancer receiving external beam PBI, 40 Gy/15 fractions/3 weeks.Localization of the tumor bed on the planning CT scan, the use of respiratory-gating, coverage of the clinical target volume (CTV), and doses to organs at risk were collected. RESULTS: Respiratory-gating was used in 123 patients (53 %). In 176 patients (77 %) the tumor bed was in the upper and in 54 patients (23 %) in the lower breast quadrants. The median MHD was 0.37 Gy (interquartile range 0.26-0.57 Gy), 0.33 Gy (0.23-0.49 Gy) for respiratory-gating, and 0.49 Gy (0.31-0.70 Gy) for free breathing, p < 0.0001. MHD was < 1 Gy in 206 patients (90 %) and < 2 Gy in 221 patients (96 %). Respiratory-gating led to significantly lower MHD for upper-located, but not for lower-located tumor beds, however, all MHD were low irrespective of respiratory-gating. Respiratory-gating did not improve CTV coverage or lower lung doses. CONCLUSIONS: PBI ensured a low MHD for most patients. Adding respiratory-gating further reduced MHD for upper-located but not for lower-located tumor beds but did not influence target coverage or lung doses. Respiratory-gating is no longer DBCG standard for left-sided PBI.
引用
- Høgsbjerg KW, Maae E, Nielsen MH, et al. Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial. Radiother Oncol. 2024. PMID: 38442840. doi:10.1016/j.radonc.2024.110195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。